Highly Active Antiretrovirl Therapy for Kaposi's sarcoma or Infection with the Kaposi's sarcoma-associated Herpes Virus in HIV infection: This is a trial that tests the effects of anti-HIV therapy on Kaposi's sarcoma for people who have relatively mild Kaposi's sarcoma that may not need specific anti-Kaposi's sarcoma therapy. It is also for HIV infected people who are also infected with the Kaposi's sarcoma-associated herpes virus that in part causes Kaposi's sarcoma.

Growth factor blockade for treatment of Kaposi's sarcoma: : This is a clinical trial to investigate whether blocking VEGF (thought to be a major growth factor for KS) will result in positive well tolerated treatment effects in KS.

Chemotherapy with Rituximab for Recurrent AIDS-associated non-Hodgkin's Lymphoma: This is a trial exploring the use of infusional chemotherapy with rituximab for relapsed AIDS-associated NHL. This trial is being conducted in collaboration with the Medicine Branch, DCS, NCI.

Short-Course Chemotherapy AIDS-associated non-Hodgkin's Lymphoma: This is a trial that explores the use of infusional chemotherapy combined with the monoclonal antibody rituximab to determine if it is possible to achieve long-term lymphoma remission with as few as 2 to 3 cycles of chemotherapy.

Note: Information about all of these trials can be obtained by calling (301) 496-8959, or (800) 243-2732 and then press 4 at the recording. This is a direct line to the NCI Adult AIDS Group. If nobody answers, please leave a message with your phone number and/or address on voice mail and we will get back to you shortly. You can leave messages for the specific research nurse involved with these trials whose names are listed by the full description of each clinical trial.

Patient-volunteers from throughout the United States are invited to participate in trials for which they are eligible. Patient-volunteers will have to pay for the first trip to the NIH, but subsequent travel to participate in a clinical research trial at the NIH will be paid for by HAMB for people living far away from the NIH. If overnight stays are necessary, a daily allowance to help defer these costs is also provided, after the initial visit.

All these trials are open to persons 18 years or older without regard to their sex, race, ethnic origin, or religion. These are experimental therapies in which the risks are not known. The decision to enter a study should be made between the patient and his or her referring physician, and patients should make sure to read and understand the informed consent before volunteering. Questions may be answered by the contact persons listed or by Dr. Richard Little (email: rlittle@helix.nih.gov ), or by Dr. Robert Yarchoan, (email: yarchoan@helix.nih.gov ) by calling (301) 496-8959, or (800) 243-2732 and then press 4 at the recording.